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ABSTRACT. 1 
OBJECTIVE. To describe a new immunoprecipitation pattern identified in Italian patients affected 2 
by systemic sclerosis (SSc), corresponding to the pyruvate dehydrogenase antigen complex 3 
recognized by anti-mitochondrial antibodies (AMA) in primary biliary cholangitis (PBC).  4 
METHODS. Autoantibodies in sera from 85 patients with SSc were tested by protein- and RNA-5 
immunoprecipitation. Immunoprecipitation-Western blot was used to determine the identified 6 
proteins, and medical records re-evaluated for liver function tests and PBC.  7 
RESULTS. In 13/85 (15%) SSc sera, a unique set of 75-50-40-34kd proteins that had not been 8 
previously reported, was noted.  The four proteins were identified as the proteins X/E3BP, E1α, 9 
E1β, and E2/E3 of the pyruvate dehydrogenase antigen complex by immunoprecipitation-Western 10 
blot. From clinical record evaluation, 9/13 (69%) SSc patients with this new pattern were positive 11 
for AMA by routine indirect immunofluorescence, and 7/13 (54%) had a diagnosis of PBC, while 12 
4/13 (31%) manifested no biochemical signs of cholestasis. Twelve of 13 patients with SSc and 13 
AMA by immunoprecipitation have a limited cutaneous form of SSc and anti-centromere 14 
antibodies.  15 
CONCLUSIONS. We describe a pattern of 4 proteins in 15% of SSc patients, identified for the 16 
first time by protein-immunoprecipitation. This pattern corresponds to serum AMA against the 17 
pyruvate dehydrogenase antigen complex and it must be considered in the interpretation of protein-18 
immunoprecipitation results.  19 
 20 
Key words: autoimmunity; scleroderma; autoimmune cholangitis; pyruvate dehydrogenase; 21 
immunoprecipitation 22 
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INTRODUCTION 1 
A large proportion of patients with systemic sclerosis (SSc) manifest a coexisting autoimmune 2 
condition, including primary biliary cholangitis (PBC) [1, 2]. As immunoprecipitation (IP) is 3 
currently one of the most sensitive techniques to detect new and known rare autoantibodies, a clear 4 
understanding of common patterns is necessary for proper interpretation of the results. Anti-5 
mitochondrial autoantibodies (AMA) are the hallmark of PBC [3-5] and in clinical practice they  6 
may predate the clinical onset of disease [6, 7] when tested with routine indirect 7 
immunofluorescence performed on tissue slides, while the use of alternative techniques such as 8 
ELISA for mitochondrial antigens still is not routinely used and it has unclear clinical significance 9 
[8]. PBC is associated with other autoimmune diseases in about 30% of patients, with SSc found in 10 
7-12% of cases [1, 2], even though in clinical practice a higher percentage of SSc patients may have 11 
biochemical liver abnormalities without clinical significance [9].  12 
We herein used IP to test new and uncommon serum autoantibodies in SSc and in this screening 13 
analysis we observed that 15% of SSc sera manifest a novel IP pattern, comprising a set of 4 14 
proteins corresponding to the E1α, E1β, protein X/E3BP, and E2/E3 subunits of the pyruvate 15 
dehydrogenase complex (PDC) recognized by AMA [10-12]. The prevalence of AMA by IP 16 
outnumbers what is observed in routine tests in our cohort of SSc patients and this new IP pattern 17 
should be known when interpreting IP data in SSc sera.  18 
 19 
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PATIENTS AND METHODS 1 
Subjects. 2 
Eighty-five consecutive patients with SSc attending the outpatient Rheumatology clinic at 3 
Humanitas Research Hospital (Rozzano, Milan, Italy) between 2012 and 2016, were enrolled to the 4 
study. Controls included sera from 74 healthy subjects, 49 patients with 5 
polymyositis/dermatomyositis (PM/DM), 32 patients with undifferentiated connective-tissue 6 
disease (UCTD), and 2 patients with established PBC previously AMA-positive and negative for 7 
serum antinuclear antibody (ANA) without signs of rheumatic diseases. Internationally accepted 8 
criteria were used for the diagnosis of SSc [13], PM/DM [14], UCTD [15], and PBC [16] and we 9 
collected clinical and laboratory data at enrollment. SSc patients who did not fulfill the 10 
ACR/EULAR criteria were defined as sine SSc [17] and very early diagnosis of SSc (VEDOSS) 11 
[18]. Liver laboratory tests included in our study are aspartate aminotransferase (AST), alanine 12 
aminotransferase (ALT), gamma glutamyltransferase (gammaGT), alkaline phosphatase (ALP), 13 
bilirubin (total, direct) and, when available, liver histology was also evaluated. The study was 14 
approved by the Institutional Review Board of the Humanitas Research Hospital and a signed 15 
informed consent was obtained from all subjects in accordance with the Declaration of Helsinki and 16 
its subsequent modifications. 17 
 18 
Methods. 19 
Protein- and RNA-immunoprecipitation (IP) 20 
Sera were obtained from whole blood through centrifugation at 2000g for 15 minutes, and then 21 
stored in -20°C freezer until use. Serum autoantibodies were screened by protein-IP using 35S-22 
methionine-labeled K562 cell extract followed by SDS-PAGE and autoradiography, and by RNA-23 
IP using unlabeled K562 cell extract followed by urea-PAGE and silver staining [19, 20]. 24 
Autoantibodies were analyzed using reference sera obtained from the Autoantibody Standardization 25 
Committee (www.autoab.org) and from internal controls, and they were used for the correct 26 
 5 
interpretation of protein-IP bands for known ANA specificities. These reference sera help in 1 
determining protein-IP specificities for ANA in connective tissue diseases and are used also for SSc 2 
patients as in our cohort. 3 
 4 
IP-Western Blot (IP-WB) 5 
Sera with a novel IP pattern of a set of 4 proteins were tested by IP-WB. In detail, 50µl of candidate 6 
sera were cross-linked with protein-A Sepharose beads and then immunoprecipitated with cell 7 
extract from 5x106 K562 cells/sample. Proteins were then fractionated by 8% SDS-PAGE and 8 
transferred to a nitrocellulose filter, probed with 1:500 of mouse polyclonal anti-human PDH E1α 9 
antibody (Novus Biologicals, Littleton, CO, USA) for a 41 kD protein identification, followed by 10 
horseradish peroxidase (HRP) goat anti-mouse IgG (1: 10 000 dilution; ThermoFisher, Waltham, 11 
MA, USA). The same procedure was used to identify the other bands of the complex: mouse anti-12 
human PDH E1β (1: 500 dilution; Novus Biological, Littleton, CO, USA) for the protein of 34 kD; 13 
mouse anti-human PDH protein X/E3BP (1: 1000 dilution; Novus Biological, Littleton, CO, USA) 14 
for the 54kD; mouse anti-human PDH E2/E3 proteins of 58kD and 74kD (1: 10,000 dilution; 15 
Abcam, Cambridge, UK) followed by goat anti-mouse IgG (ThermoFisher, Waltham, MA, USA). 16 
Development was performed by Immobilon Western Chemiluminescent HRP substrate (Millipore, 17 
Darmstadt, Germany) and acquired using ChemiDoc (Bio-Rad, California, USA). 18 
 19 
Indirect immunofluorescence (IIF) 20 
Antinuclear and cytoplasmic antibodies were tested by IIF on HEp-2 ANA slides (INOVA 21 
Diagnostics, San Diego, CA, USA) using a 1:80 dilution of human sera of patients and controls, 22 
followed by AlexaFluor488 AffiniPure F(ab')2 fragment goat anti-human IgG, Fcγ fragment 23 
specific (Jackson Immunoresearch Europe Ltd, Suffolk, UK) as previously described [19]. Images 24 
were acquired on Olympus BX53 Upright fluorescence microscope. No immunofluorescence 25 
analysis on tissue slides was performed for AMA identification.  26 
 6 
 1 
ELISA 2 
Positive serum AMA identified by protein-IP (n=13) were tested for confirmation by ELISA using 3 
the QUANTA Lite M2 EP (MIT3) IgG ELISA (INOVA Diagnostics, Inc, San Diego, USA) with 4 
the patented pMIT3 antigen, which consists of a recombinant protein containing the 5 
immunodominant epitopes of the 3 major AMA targets [21], currently limited to research settings. 6 
ELISA was performed according to the manufacturer instructions, and results were shown as Units.  7 
 8 
Statistical analysis 9 
All comparisons were performed by Fisher’s exact test using Prism version 5.0 (GraphPad 10 
Software, Inc., La Jolla, CA, USA). All analyses were two-tailed and P values <0.05 were 11 
considered as statistically significant. 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 7 
RESULTS 1 
Demographic and laboratory data of the SSc cohort.  2 
We included 85 patients (81 women, mean age ± standard deviation 66±15 years) with SSc and 3 
their sera were studied by IP. The age at SSc onset was 53 ± 15 years, and the mean follow-up was 4 
106 months (range 4 to 408). From clinical record retrospective evaluation, nine patients with 5 
limited cutaneous SSc had a previous diagnosis of PBC with available liver biopsy, and in one 6 
patient an overlap with ANA-positive autoimmune hepatitis was found. In 5/9 (56%) PBC cases, 7 
the onset of chronic cholestasis preceded the diagnosis of SSc (range 1-24 years), while in 4/9 8 
(44%) the diagnosis of PBC followed SSc by 3-24 years. Additional features of our SSc cohort are 9 
described in Table 1. Fourteen cases defined as sine SSc [17] (n=4) and very early diagnosis of SSc 10 
(VEDOSS, [18], n=10) are not included in the statistical evaluation shown in Table 1, but two 11 
AMA-positive IP cases were identified in sine SSc patients defined by ACA-positivity, Raynaud’s 12 
phenomenon and capillaroscopy alterations but no signs of skin fibrosis.  13 
 14 
Autoantibody analysis. 15 
By protein-IP we observed a new pattern with a set of 4 proteins of 75-50-40-34kd molecular 16 
weight (Figure 1) in 13/85 (15%) SSc sera, while no RNA band was detected by RNA-IP in these 17 
patients. The protein-IP pattern was observed also in the two AMA-positive PBC cases, and in one 18 
patient with UCTD without sign of liver disease suggestive for PBC, while no PM/DM manifested 19 
such pattern. We could identity each protein immunoprecipitated by these sera using IP-WB 20 
(Figure 2) as the E1α, E1β, E2/E3 and protein X/E3BP subunits of the mitochondrial pyruvate 21 
dehydrogenase complex.   22 
The main features of SSc cases with the new protein-IP profile are summarized in Table 2, and a 23 
comparison between AMA-positive and AMA-negative limited cutaneous SSc patients is described 24 
in Table 3. From a clinical viewpoint, 8/13 (61.5%) SSc patients with the AMA protein-IP profile 25 
we describe for the first time were positive for serum AMA by routine IIF on tissue slides, while 26 
 8 
5/13 (38.5%) SSc patients tested negative and had no cytoplasmic staining was reported by routine 1 
IIF on Hep-2 slides; among these, 6/13 (46%) had a pre-existing diagnosis of PBC. In our cohort 2 
AMA-positive SSc patients have a limited cutaneous form and they are significantly associated with 3 
ACA positivity (Table 3), and only one AMA-positive case has diffuse cutaneous SSc.  4 
The pMIT3 ELISA results were in agreement with the new protein-IP profile in 13/13 (100%) sera 5 
but we should note that this serology method is currently used only for research purposes. ACA-6 
positive IIF pattern with cytoplasmic staining at different titer is present in 12/13 (92.3%) AMA-7 
positive SSc cases, and in one case we had anti-cytoplasmic, nuclear speckled+nucleolar pattern by 8 
IIF (Figure 3).  9 
 10 
11 
 9 
DISCUSSION. 1 
Serum autoantibodies remain the most commonly used and helpful biomarker in the diagnosis and 2 
treatment of autoimmune diseases and may precede the clinical manifestations by several years, as 3 
reported in systemic lupus erythematosus [22] and rheumatoid arthritis [23]. In some cases, 4 
however, serum autoantibodies such as ANA are detected in non-rheumatic conditions or may be 5 
falsely positive due to technical issues, particularly at low titer [24], while other autoantibodies have 6 
strong clinical associations such as anti-topo I/Scl70 being frequently associated with diffuse 7 
cutaneous SSc [25]. Indeed, PBC and SSc represent unique conditions because they often coexist 8 
despite being considered rare [1] and they manifest serum autoantibodies with high specificity, 9 
represented by AMA and ACA, respectively. 10 
The diagnosis of PBC in patients with rheumatic diseases may be challenging until the clinical and 11 
laboratory expression of the disease, although it has been suggested that AMA-positive 12 
asymptomatic subjects will eventually develop PBC and that an early use of ursodeoxycholic acid 13 
may improve prognosis [26]. The serological scenario of SSc is further complicated by the recent 14 
description of several rare autoantibodies associated with SSc [27]. These new autoantibodies are 15 
identified first by IP in research laboratories and then validated by other techniques to be ultimately 16 
used in clinical practice, as in the case of recently identified autoantibodies in PM/DM [28]. Based 17 
on this rationale, identifying and sharing common patterns by IP is necessary to allow the testing of 18 
new and rare autoantibodies, and to improve the interpretation of IP results. 19 
We herein report for the first time the IP pattern of serum AMA in SSc and the prevalence of PBC-20 
associated autoantibodies even in the absence of biochemical sign of cholestasis, through the 21 
identification of a set of 4 proteins that correspond to the subunits of the pyruvate dehydrogenase 22 
complex. The conventional pattern of AMA detected in sera from PBC was first described by 23 
techniques such as immunoblot and showed the reactivity of PBC sera with components of the PDC 24 
complex, namely E1α/β, E2, E3 and the protein X later identified as E3BP [29]. The novelty of our 25 
finding is based on the description for the first time of a protein-IP pattern that corresponds to the 26 
 10 
antigenic subunits recognized by AMA, which has never been described before. This identity of the 1 
proteins identified in this new protein-IP pattern was confirmed using the currently available 2 
ELISA, yet not routinely used, i.e. the recombinant pMIT3 antigen [21], and the IP-WB technique. 3 
It is possible that AMA positivity we observed by protein-IP may also include the reactivity only of 4 
some of the presented bands but this was not observed in our series. Further, we report that 15% of 5 
SSc sera are positive for AMA, a significant prevalence as demonstrated also by previous reports 6 
with up to 25% AMA positivity in SSc patients [8], and ACA are reported in up to 30% of patients 7 
with PBC [30].  8 
Our data demonstrate that one laboratory technique, protein-IP, could be sufficient to achieve two 9 
goals: to screen for autoantibodies in rheumatic patients such as SSc and to identify coexisting 10 
autoantibodies that discriminate comorbidities. Moreover, we are currently living in an era 11 
characterized by the use of automatic screening method for ANA identification that often do not 12 
include the cytoplasmic pattern in AMA-positive patients, thus we could overcome this problem by 13 
using IP alone. Nonetheless, we are aware that protein-IP has a limited feasibility in the routine 14 
laboratory due to the labor and time-consuming protocols and the significant costs. 15 
Four patients with SSc and the new protein-IP pattern had no sign of PBC nor tested AMA positive 16 
by IIF and this is particularly intriguing as the use of pMIT3-based ELISA has been shown to 17 
reduce the proportion of AMA-negative PBC cases and was in 100% agreement with protein-IP, 18 
confirming the identity of the protein pattern we observed [31]. Our results have three possible 19 
implications. First, we may speculate that AMA detected by protein-IP are more sensitive and 20 
possibly appear earlier than IIF-AMA on tissue slides, and they could be recognized in an early 21 
phase of autoantibodies screening. Second, previous studies on the coexistence of PBC and SSc 22 
may have underestimated the prevalence of the association, as AMA are usually detected when a 23 
clinical or laboratory suspect of PBC is present [8]. We are well aware that AMA positivity in the 24 
absence of biochemical cholestasis should be further investigated by liver histology to confirm the 25 
presence of  PBC but this is currently not advisable for ethical reasons nor a diagnosis at 26 
 11 
asymptomatic stages would change the natural history of PBC despite the use of ursodeoxycholic 1 
acid [32]. Third and last, we confirm that AMA and PBC are associated with the limited cutaneous 2 
form of SSc and positivity of ACA, and liver disease does not seem to worsen the prognosis of our 3 
AMA-positive patients with SSc [2].  4 
In conclusion, we describe for the first time the protein-IP pattern of AMA and we demonstrate for 5 
the first time that protein-IP can be used for AMA detection in our SSc cohort of patients. In 15% of 6 
our SSc cases, in fact, a new AMA IP pattern was detected and characterized as a set of 4 proteins 7 
corresponding to the subunits of the pyruvate dehydrogenase antigen complex, as described decades 8 
ago only by immunoblot [29]. The definition of this protein-IP pattern is mandatory in the 9 
interpretation of protein-IP, increasingly used for rare autoantibody detection in clinical practice. 10 
Ultimately, we could also speculate that IP-AMA are earlier predictors of PBC compared to routine 11 
AMA on tissue slides, similar to the predictive role of AMA in patients without cholestasis, but this 12 
needs to be verified in a larger prospective cohort.  13 
 14 
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TABLES. 1 
TABLE 1. Main features of the limited and diffuse cutaneous SSc cohort analyzed for AMA 2 
identification by protein-IP. Only p values <0.05 are reported. Fourteen cases defined as sine SSc 3 
(n=4) and VEDOSS (n=10) are not included in the present table. 4 
 Limited 
cutaneous 
SSc  
(n=59) 
Diffuse 
cutaneous 
SSc 
(n=12) 
p values 
PBC cases, % (n.cases) 13 (8) 8 (1) ns 
Interstitial lung disease, % (n.cases) 25 (15) 67 (8) 0.014 
Pulmonary hypertension, % (n.cases) 24 (14) 42 (5) ns 
AMA by IP, % (n.cases) 17 (10) 8 (1) ns 
ACA, % (n.cases) 59 (35) 33 (4) ns 
ANA nucleolar, % (n.cases) 10 (6) 0  ns 
ANA homogeneous, % (n.cases) 8 (5) 0 ns 
Anti-topo1/Scl-70, % (n.cases) 5 (3) 50 (6) <0.001 
Anti-RNAPIII, % (n.cases) 0 8 (1) ns  
Abbreviations: ACA= anti-centromere antibodies; AMA= anti-mitochondrial antibodies; 5 
ANA=anti-nuclear antibodies; IP= immunoprecipitation; PBC=primary biliary cholangitis; 6 
RNAPIII= RNA polymerase III 7 
 8 
 13 
TABLE 2. Demographic, clinical and laboratory features of SSc patients with detectable AMA by protein-IP.  
Patient # 1 2 3 4 5 6 7 8 9 10 11 12 13 
Demography              
Sex F F F F F F F F F F F F M 
Age, years 72 76 70 56 40 63 54 81 49 58 77 59 87 
SSc 
SSc year of onset 
sine 
2005 
L 
2010 
L 
2009 
L 
- 
L 
2006 
L 
2007 
L 
2010 
sine 
- 
L 
2006 
L 
2003 
L 
1981 
L 
2007 
D 
2001 
PBC diagnosis, year 2004 - 2003 - - 2006 - - 2013 
(+AIH) 
2006 2005 2011 1999 
Liver cirrhosis - - + - - - -  - - + - - -  
Autoantibodies              
ACA (+) + + + + + + + + + + + + + 
Other autoAbs - - - - ANCA 
aPLs 
- - - - Ro/SSA - - Scl70 
Laboratory              
High bilirubin - n/a + n/a - - + - - - n/a - - 
High gammaGT - n/a + + - + - - + + + + - 
High ALP - n/a + n/a - + - - + + + - - 
High AST/ALT - - + - - - - - + - + - - 
Therapy              
 14 
UDA therapy + - + - - + - - + + + + + 
Immunosuppressive 
therapy for PBC 
- - - - - - - - PDN, 
AZA 
PDN,  
AZA 
- - - 
(PDN, 
AZA,
CTX 
for 
SSc) 
Abbreviations: ACPA= Anti cyclic-citrullinated peptide antibodies; ALP= alkaline phosphatase; ALT= alanine aminotransferase; aPLs= anti-
phospholipid antibodies; AIH= autoimmune hepatitis; AMA= anti-mitochondrial antibodies; ANCA= anti neutrophil cytoplasmic antibodies; AST= 
aspartate aminotransferase; AZA= azathioprine; CTX=cyclophosphamide; D= diffuse SSc; gammaGT= gamma glutamyltransferase; IIF= indirect 
immunofluorescence; L= limited SSc; MTX= methotrexate; n/a= not available; PDN= prednisone; SSc= systemic sclerosis; UDA= 
ursodeoxycholic acid.
 1 
Table 3. Comparison of main clinical and laboratory features in patients with limited 
cutaneous SSc based on serum AMA IP positivity. Two AMA-positive cases sine SSc and one 
AMA-positive diffuse SSc patient are not included in the present table. Only p values <0.05 are 
reported.  
 AMA positive 
n= 10 
AMA negative 
n=49 
p value 
Interstitial lung disease, % 8  28  ns 
Pulmonary hypertension, % 0 26  ns 
ACA, %  100  51  0.004 
ANA nucleolar, % 0 12  ns 
Anti-topo1/Scl-70, % 0 6  ns 
Anti-RNAPIII, % 0 0 - 
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FIGURE LEGENDS.  
Figure 1. IP pattern of AMA-positive patients. The protein-IP pattern of the 75-50-40-34kD 
proteins (black arrows) of the mitochondrial complex antigen is shown in 13 SSc patients. IP 
results in 8% SDS-PAGE gel are shown. PBC #1 and PBC #2 represent two cases with isolated 
diagnosis of PBC and PBC #2 was known to have weak positivity for AMA by routine IIF on tissue 
slides and ELISA. Normal human serum is included as negative control.  
Figure 2. IP-WB confirming the identity of the IP bands corresponding to the mitochondrial 
antigen complex components. The samples tested by IP-WB are the same shown in Figure 1 for 
protein-IP, with positivity for the IP-AMA pattern as described, and their main features are 
described in Table 2. The molecular weight marker (MWM) is shown for reference, and IP-WB for 
each component confirms the identity of protein X/E3BP, E1α, E1β and E2/E3 corresponding to the 
54kD, 41kD, 34kD, 74/58kD of the proteins shown in protein-IP, respectively.  
Figure 3. Indirect immunofluorescence of AMA-positive SSc cases detected by protein-IP. 
HEp-2 ANA slides were used to analyze the immunofluorescence pattern of  AMA-positive SSc 
cases (a to m), or normal human serum (n). Serum dilution, 1:80. ACA-positive with cytoplasmic 
staining at different titer is present in 12/13 AMA-positive SSc cases (a to l), and in one case we 
had a cytoplasmic staining associated with positive anti-nuclear and nucleolar immunofluorescence 
staining (m).  
